First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (HuMax-AXL-ADC) in Patients With Solid Tumors

Trial Profile

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (HuMax-AXL-ADC) in Patients With Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs HuMax AXL ADC (Primary)
  • Indications Cervical cancer; Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man
  • Sponsors Genmab
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 20 Apr 2017 According to a Genmab media release, a description of this trial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top